{"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:story:334b8b16-9b1f-4d45-adea-d6a92e625aef", "type": "composite", "version": "1", "versioncreated": "2026-11-11T06:52:38.892645Z", "firstcreated": "2026-11-11T05:55:45.388347Z", "pubstatus": "usable", "language": "es", "headline": "La FDA exigirá advertir sobre un posible riesgo de pérdida de visión con fármacos GLP-1", "description_text": "La Administración de Alimentos y Medicamentos de Estados Unidos (FDA) pedirá que las etiquetas de Ozempic, Wegovy, Zepbound y Mounjaro incluyan una advertencia sobre la neuropatía óptica isquémica anterior no arterítica, una rara lesión del nervio óptico que puede causar pérdida de visión repentina y, a menudo, permanente.", "associations": {"item-0": {"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:e4c6b113-1044-4948-aba4-aa948d927195", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-11-11T06:00:38.678177Z", "firstcreated": "2026-11-11T05:55:45.388347Z", "pubstatus": "usable", "urgency": 5, "language": "es", "headline": "La FDA exigirá advertir sobre un posible riesgo de pérdida de visión con fármacos GLP-1", "byline": "Elena Lozano", "located": "Spain", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Evolut", "usageterms": "Subscribers may republish this item in full, including translation and trimming, with the credit “Wireva / Evolut”. Set rel=canonical to https://evolut.top/sociedad/la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1/ when publishing on the web.", "description_text": "La Administración de Alimentos y Medicamentos de Estados Unidos (FDA) pedirá que las etiquetas de Ozempic, Wegovy, Zepbound y Mounjaro incluyan una advertencia sobre la neuropatía óptica isquémica anterior no arterítica, una rara lesión del nervio óptico que puede causar pérdida de visión repentina y, a menudo, permanente.", "altids": {"mosaic": "e4c6b113-1044-4948-aba4-aa948d927195", "story": "334b8b16-9b1f-4d45-adea-d6a92e625aef", "slug": "la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1"}, "subject": [{"name": "Society", "rel": "direct", "literal": "society", "code": "medtop:14000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/14000000"}], "place": [{"name": "Spain", "literal": "es", "code": "ES", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:365ddbd0-e163-4b70-9fe9-8e6014d55a87", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "FDA alerta sobre posible riesgo de pérdida de visión ligado a fármacos GLP-1", "description_text": "La FDA exigirá advertir sobre un posible riesgo de pérdida de visión con fármacos GLP-1", "copyrightholder": "nbg1.your-objectstorage.com", "copyrightnotice": "Wireva desk", "usageterms": "Supplied with the copy; origin to be confirmed by the desk before redistribution.", "altids": {"wireva": "365ddbd0-e163-4b70-9fe9-8e6014d55a87"}, "extra": {"wireva:delivery_mode": "preview_and_link", "wireva:rights": {"licence": "Desk-supplied", "licence_url": "", "licence_raw": "Manual upload", "licence_verified_at": "2026-11-11T06:55:38.786925Z", "attribution_required": true, "attribution_text": "Wireva desk", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "nbg1.your-objectstorage.com", "source_url": "https://nbg1.your-objectstorage.com/ckln/manual-news/trends-208-ES-3.jpg", "source_page_url": "https://nbg1.your-objectstorage.com/ckln/manual-news/trends-208-ES-3.jpg", "our_page_url": "https://claroscuro.fans/sociedad/la-fda-exigira-advertir-sobre-riesgo-de-perdida-de-vision-con-farmacos-glp-1/"}, "wireva:role": "lead"}, "renditions": {"preview": {"href": "https://nbg1.your-objectstorage.com/ckln/image-assets/e44ad14f19a697ea06c0126b0855f7bcc03197eee2753f6bdc01a094bc95e2d3.jpg", "mimetype": "image/jpeg", "width": 840, "height": 504}, "source": {"href": "https://nbg1.your-objectstorage.com/ckln/manual-news/trends-208-ES-3.jpg", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:334b8b16-9b1f-4d45-adea-d6a92e625aef", "slug": "la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1-20261111", "status": "updated", "languages": ["es"], "item_count": 2, "is_breaking": false}, "wireva:rights": {"class": "owned", "redistribution_allowed": true, "commercial_use_allowed": true, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Evolut", "canonical_required": true, "canonical_url": "https://evolut.top/sociedad/la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1/", "linkback_required": true, "licence": "Wireva subscriber licence", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 0, "decided_by_rule": "own_production", "needs_review": false}, "wireva:provenance": {"production_method": "ai_assisted", "ai_stages": {"editing": true, "drafting": true, "headline": true, "image_selection": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "unverified", "independent_confirmations": 0, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "Este artículo se ha producido con ayuda de IA bajo la responsabilidad editorial de Haydamax OÜ.", "independence_check": {"status": "not_applicable", "score": 0.0, "checked_at": "2026-11-11T06:00:38.692357Z"}, "sources": []}, "wireva:publication": {"name": "Evolut", "domain": "evolut.top", "country": "ES", "url": "https://evolut.top/sociedad/la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/e4c6b113-1044-4948-aba4-aa948d927195", "html": "https://wireva.mib.news/item/e4c6b113-1044-4948-aba4-aa948d927195/la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1/", "story": "https://wireva.mib.news/story/la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1-20261111/"}, "wireva:metrics": {"word_count": 510, "char_count": 3169, "reading_time_seconds": 226}}}, "item-1": {"$schema": "https://iptc.org/std/ninjs/ninjs-schema_3.2.json", "uri": "urn:newsml:wireva.mib.news:item:69736b66-9950-4094-b588-b11ef7b05e41", "type": "text", "profile": "standard", "version": "1", "versioncreated": "2026-11-11T06:55:38.770742Z", "firstcreated": "2026-11-11T06:52:38.892645Z", "pubstatus": "usable", "urgency": 5, "language": "es", "headline": "La FDA exigirá advertir sobre riesgo de pérdida de visión con fármacos GLP-1", "byline": "Alba Aguilar", "located": "Spain", "copyrightholder": "Haydamax OÜ", "copyrightnotice": "Wireva / Claroscuro", "usageterms": "Subscribers may republish this item in full, including translation and trimming, with the credit “Wireva / Claroscuro”. Set rel=canonical to https://claroscuro.fans/sociedad/la-fda-exigira-advertir-sobre-riesgo-de-perdida-de-vision-con-farmacos-glp-1/ when publishing on the web.", "description_text": "La Administración de Alimentos y Medicamentos de Estados Unidos incluirá una advertencia en las etiquetas de los medicamentos GLP-1 por el posible vínculo con una neuropatía óptica que puede causar pérdida súbita de visión. La agencia aclara que no se ha demostrado una relación causal.", "altids": {"mosaic": "69736b66-9950-4094-b588-b11ef7b05e41", "story": "334b8b16-9b1f-4d45-adea-d6a92e625aef", "slug": "la-fda-exigira-advertir-sobre-riesgo-de-perdida-de-vision-con-farmacos-glp-1"}, "subject": [{"name": "Society", "rel": "direct", "literal": "society", "code": "medtop:14000000", "scheme": "http://cv.iptc.org/newscodes/mediatopic/", "uri": "http://cv.iptc.org/newscodes/mediatopic/14000000"}], "place": [{"name": "Spain", "literal": "es", "code": "ES", "scheme": "http://cv.iptc.org/newscodes/countrycodes/"}], "person": [], "organisation": [], "genre": [{"name": "Standard story", "literal": "standard"}], "service": [{"name": "Wireva", "literal": "wireva"}], "associations": {"featuremedia": {"uri": "urn:newsml:wireva.mib.news:media:365ddbd0-e163-4b70-9fe9-8e6014d55a87", "type": "picture", "version": "1", "pubstatus": "usable", "headline": "FDA alerta sobre posible riesgo de pérdida de visión ligado a fármacos GLP-1", "description_text": "La FDA exigirá advertir sobre un posible riesgo de pérdida de visión con fármacos GLP-1", "copyrightholder": "nbg1.your-objectstorage.com", "copyrightnotice": "Wireva desk", "usageterms": "Supplied with the copy; origin to be confirmed by the desk before redistribution.", "altids": {"wireva": "365ddbd0-e163-4b70-9fe9-8e6014d55a87"}, "extra": {"wireva:delivery_mode": "preview_and_link", "wireva:rights": {"licence": "Desk-supplied", "licence_url": "", "licence_raw": "Manual upload", "licence_verified_at": "2026-11-11T06:55:38.786925Z", "attribution_required": true, "attribution_text": "Wireva desk", "redistribution_allowed": false, "commercial_use_allowed": false, "modifications_allowed": false, "share_alike_required": false}, "wireva:provenance": {"creator": "", "source_name": "nbg1.your-objectstorage.com", "source_url": "https://nbg1.your-objectstorage.com/ckln/manual-news/trends-208-ES-3.jpg", "source_page_url": "https://nbg1.your-objectstorage.com/ckln/manual-news/trends-208-ES-3.jpg", "our_page_url": "https://claroscuro.fans/sociedad/la-fda-exigira-advertir-sobre-riesgo-de-perdida-de-vision-con-farmacos-glp-1/"}, "wireva:role": "lead"}, "renditions": {"preview": {"href": "https://nbg1.your-objectstorage.com/ckln/image-assets/e44ad14f19a697ea06c0126b0855f7bcc03197eee2753f6bdc01a094bc95e2d3.jpg", "mimetype": "image/jpeg", "width": 840, "height": 504}, "source": {"href": "https://nbg1.your-objectstorage.com/ckln/manual-news/trends-208-ES-3.jpg", "mimetype": "image/jpeg"}}}}, "extra": {"wireva:story": {"uri": "urn:newsml:wireva.mib.news:story:334b8b16-9b1f-4d45-adea-d6a92e625aef", "slug": "la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1-20261111", "status": "updated", "languages": ["es"], "item_count": 2, "is_breaking": false}, "wireva:rights": {"class": "owned", "redistribution_allowed": true, "commercial_use_allowed": true, "modifications_allowed": true, "share_alike_required": false, "attribution_required": true, "attribution_text": "Wireva / Claroscuro", "canonical_required": true, "canonical_url": "https://claroscuro.fans/sociedad/la-fda-exigira-advertir-sobre-riesgo-de-perdida-de-vision-con-farmacos-glp-1/", "linkback_required": true, "licence": "Wireva subscriber licence", "licence_url": "", "licensor": "Haydamax OÜ", "valid_until": null, "excerpt_max_chars": 0, "decided_by_rule": "own_production", "needs_review": false}, "wireva:provenance": {"production_method": "ai_assisted", "ai_stages": {"editing": true, "drafting": true, "headline": true, "image_selection": true}, "model": "", "human_reviewed": false, "reviewed_by": "", "reviewed_at": null, "editorial_control": true, "editorial_responsibility": "Haydamax OÜ (Wireva)", "factchecked": false, "verification_status": "unverified", "independent_confirmations": 0, "official_source_used": false, "used_press_release": false, "public_interest": true, "ai_disclosure_required": true, "ai_disclosure_text": "Este artículo se ha producido con ayuda de IA bajo la responsabilidad editorial de Haydamax OÜ.", "independence_check": {"status": "not_applicable", "score": 0.0, "checked_at": "2026-11-11T06:55:38.782626Z"}, "sources": []}, "wireva:publication": {"name": "Claroscuro", "domain": "claroscuro.fans", "country": "ES", "url": "https://claroscuro.fans/sociedad/la-fda-exigira-advertir-sobre-riesgo-de-perdida-de-vision-con-farmacos-glp-1/"}, "wireva:links": {"self": "https://wireva.mib.news/api/v1/items/69736b66-9950-4094-b588-b11ef7b05e41", "html": "https://wireva.mib.news/item/69736b66-9950-4094-b588-b11ef7b05e41/la-fda-exigira-advertir-sobre-riesgo-de-perdida-de-vision-con-farmacos-glp-1/", "story": "https://wireva.mib.news/story/la-fda-exigira-advertir-sobre-un-posible-riesgo-de-perdida-de-vision-con-farmacos-glp-1-20261111/"}, "wireva:metrics": {"word_count": 430, "char_count": 2781, "reading_time_seconds": 199}}}}, "extra": {"wireva:languages": ["es"], "wireva:status": "updated", "wireva:item_count": 2}}